FDA Update: Committee Recommends 2 mg Baricitinib Approval; HLH Identified as Serious Adverse Event for Lamotrigine
International Approvals for Guselkumab & Anakinra; Plus Adalimumab Biosimilar in Europe
Upadacitinib Proves Superiority to Adalimumab in Phase 3 RA Study
AbbVie, Samsung Bioepis in Deal; Humira Biosimilar U.S. Release in 2023
The ACR Updates Biosimilar Position Statement
DMARDs & Biologics Info for Rheumatology Nurses
The Science Behind Biosimilars
Ferumoxytol Injection Receives New Indication, & Application for GP2017 Moves Ahead
Etanercept Biosimilar Is Effective, Well-Tolerated for Rheumatoid Arthritis
- 1
- 2
- 3
- …
- 27
- Next Page »